An overwhelming body of evidence suggests that MTAP and the cancer suppressor gene cyclin-dependent kinase inhibitor 2A (CDKN2A) are closely situated and concurrently absent in a subset of cancers [117,118]. This evidence concerns the gene MTAP and cancer.